文献速递间质性肺疾病肺栓塞与肺血管病

尼达尼布联合西地那非在特发性肺纤维化伴右心功能障碍患者中的预设亚组分析

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01

INSTAGE试验的预设亚组分析,评估基线超声心动图右心功能障碍(RHD)对尼达尼布联合西地那非与尼达尼布单药疗效的影响。结果显示,RHD亚组间在SGRQ总分和FVC变化上无显著异质性,但联合治疗对BNP的稳定作用在RHD患者中更明显。

要点

  • RHD亚组间SGRQ和FVC变化无显著异质性。
  • 联合治疗在伴或不伴RHD患者中均显示减少FVC下降的数值趋势。
  • 联合治疗对BNP的稳定作用在基线RHD患者中更明显。

核心结论

  • 在INSTAGE试验中,尼达尼布联合西地那非与尼达尼布单药相比,对SGRQ和FVC变化的影响在伴或不伴基线超声心动图RHD患者间无显著差异。
  • 联合治疗对稳定BNP的获益在基线RHD患者中更明显。

研究设计与样本

  • INSTAGE试验的预设亚组分析,双盲随机临床试验。
  • 比较基线有RHD(n=117)与无RHD(n=156)的患者。

主要发现

  • 第12周SGRQ总分变化组间异质性P=0.74,第24周P=0.90。
  • 第12周FVC变化组间异质性P=0.58,第24周P=0.55。
  • 第24周BNP变化组间差异:有RHD者为-119.9 ng/L(95%CI -171.3至-68.5),无RHD者为-3.6 ng/L(95%CI -47.2至40.0),P<0.01。
  • 两个亚组中,尼达尼布联合西地那非对减少FVC下降均有数值上更大的效果。

临床怎么用

  • 对于IPF伴右心功能障碍患者,尼达尼布联合西地那非可能有助于稳定BNP,但需结合个体情况评估。

局限性

  • 为亚组分析,样本量有限,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: In the INSTAGE trial in patients with idiopathic pulmonary fibrosis (IPF) and severely impaired gas exchange, nintedanib plus sildenafil was associated with numerical benefits on St. George's Respiratory Questionnaire (SGRQ) total score, brain natriuretic peptide (BNP), and FVC decline versus nintedanib alone. Exploratory analyses of the STEP-IPF (Sildenafil Trial of Exercise Performance in IPF) trial suggested that sildenafil may have a greater effect on SGRQ score in patients with IPF who have right heart dysfunction (RHD).Objectives: Assess whether RHD influenced the effects of nintedanib plus sildenafil versus nintedanib alone in the INSTAGE trial.Methods: Subgroup analyses of patients with (n = 117) versus those without (n = 156) echocardiographic signs of RHD at baseline.Measurements and Main Results: There was no heterogeneity between subgroups by presence of RHD in the effect of nintedanib plus sildenafil versus nintedanib alone on change in SGRQ total score at Week 12 (P = 0.74) or Week 24 (P = 0.90), or change in FVC at Week 12 (P = 0.58) or Week 24 (P = 0.55). In both subgroups, nintedanib plus sildenafil had a numerically greater effect on reducing FVC decline versus nintedanib alone. Between-group differences in change in BNP at Week 24 were -119.9 ng/L (95% confidence interval = -171.3 to -68.5) and -3.6 ng/L (95% confidence interval = -47.2 to 40.0) in patients with and without signs of RHD at baseline, respectively (P < 0.01).Conclusions: In the INSTAGE trial, there were no significant differences in the effects of nintedanib plus sildenafil versus nintedanib alone on changes in SGRQ and FVC between patients with or without echocardiographic signs of RHD at baseline. The benefit of combination therapy on stabilizing BNP was more pronounced in patients with RHD at baseline.Clinical trial registered with www.clinicaltrials.gov (NCT02802345).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Behr J, Kolb M, Song JW, et al. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). Am J Respir Crit Care Med. 2019. PMID: 31365829. doi:10.1164/rccm.201903-0488OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。